What is HUMA's market cap?

$125.01M, based on the Nov 4 close of $0.45.

Does Humacyte pay a dividend?

No regular cash dividend has been paid in the last year.

How much of HUMA is sold short?

30.3M shares, 11.9% of float, as of Oct 15, 2026.

What sector is HUMA in?

Healthcare, in the Biotechnology industry.

NASDAQ · HUMAHealthcareBiotechnology

Humacyte, Inc. Common Stock (HUMA)

$0.4500+2.16%

Close Nov 4, 2026 · split-adjusted

Nov 3, 2026$0.44▼ 72.30% in range

Nov 3, 2025Low $0.35 · High $1.59Nov 3, 2026

What changed · written from our data

As of Nov 4, 2026

Humacyte closed at $0.45 on Nov 4, up 2.16%, 71.7% below its 52-week closing high. Volume of 2.6M shares was 0.42× its 20-day average (below normal).

Split-adjusted performance: -5.9% over one month, -54.2% over six months, -71.7% over one year.

In the quarter ended Jun 30, 2026, revenue was $406K, up 34.9% from a year earlier, with a net margin of -9064.5%.

Short interest was 30.3M shares at the Oct 15 settlement, up 2.9% from the prior report (11.9% of float, 3.7 days to cover).

Market cap$125.0M277.8M shares

Revenue · quarter$406.0K+34.9% YoY

Diluted EPS$-0.16—

P/E · TTM—P/S 58.9×

Net margin-9,064.5%Gross -203.2%

Dividend yieldNone

52-week range0.35 – 1.59−71.7% from high

Volume2.6M0.42× 20-day avg

Volatility · 60d107.9%Annualised

Short % of float11.9%3.7 days to cover

Net cash$13.7MCash $79.9M

Next earnings—Not scheduled

Split-adjusted performance

1W −4.3%1M −5.9%3M −36.6%6M −54.2%YTD −53.1%1Y −71.7%3Y −77.9%5Y −95.0%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum23

Revenue growth74

Net margin9

Value (low P/E)—

Size39

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →

Shares short30.3M+2.9% vs prior

Days to cover3.7Settled Oct 15

% of float11.9%

Short vol. 10d56.4%of daily volume

Closest peers by size in Biotechnology

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
HUMAHumacyte	$0.4500	+2.16%	−54.2%	+34.9%	−9064.5%	—	$125.0M
CHRSCoherus Oncology	$0.8502	+5.54%	−51.4%	+39.5%	−144.2%	—	$131.4M	Compare
AVXLAnavex Life Sciences	$1.26	+5.00%	−62.3%	—	—	—	$116.8M	Compare
ARMPArmata Pharmaceuticals	$3.14	+1.62%	−65.3%	+15.7%	2953.8%	—	$116.8M	Compare
ENGNenGene Therapeutics	$1.72	+6.17%	−80.6%	—	—	—	$115.3M	Compare
VYGRVoyager Therapeutics	$1.87	+2.19%	−55.2%	−39.1%	−773.2%	—	$115.2M	Compare
CMPXCompass Therapeutics	$0.7627	+1.29%	−59.2%	—	—	—	$137.4M	Compare
TARAProtara Therapeutics	$2.35	−2.49%	−58.5%	—	—	—	$138.9M	Compare
OTLKOutlook Therapeutics	$0.4621	+0.46%	+99.4%	−99.4%	−233554.9%	—	$112.5M	Compare

News about Humacyte

All news →

Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key InsightsZacks Investment Research · 5d ago▼ Negative Why Humacyte, Inc. (HUMA) Outpaced the Stock Market TodayZacks Investment Research · Oct 21, 2026▼ Negative Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to NoteZacks Investment Research · Oct 19, 2026▼ Negative Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to KnowZacks Investment Research · Oct 13, 2026▼ Negative Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You TradeZacks Investment Research · Oct 6, 2026▼ Negative

Quick answers

What does Humacyte do?: Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.
What is HUMA's market cap?: $125.01M, based on the Nov 4 close of $0.45.
Does Humacyte pay a dividend?: No regular cash dividend has been paid in the last year.
How much of HUMA is sold short?: 30.3M shares, 11.9% of float, as of Oct 15, 2026.
What sector is HUMA in?: Healthcare, in the Biotechnology industry.

About Humacyte

Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

HQ: Durham, NC184 employeesListed Aug 27, 2021humacyte.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology